Immunotherapy plus chemo shows promise in rectal cancer trial
NCT ID NCT07291401
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) to standard chemoradiotherapy before surgery can improve outcomes for people with locally advanced rectal cancer. About 108 participants will be randomly assigned to receive either the standard treatment or the standard treatment plus immunotherapy. The goal is to see if the combination leads to a higher rate of complete tumor disappearance and allows more patients to avoid surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (QL1706) combined with chemotherapy (CAPOX) and radiotherapy
What this could lead to
If successful, this could offer a more effective neoadjuvant treatment for locally advanced rectal cancer, potentially increasing the chance of complete tumor response and organ preservation.
What could go wrong
This is an early phase 2 trial with only 108 participants, so results may not apply to all patients. Adding immunotherapy to standard treatment may increase side effects, and it's unknown if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••